Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases

Ann Oncol. 2014 Apr;25(4):912-913. doi: 10.1093/annonc/mdu041.

Authors

S Gori¹, G Lunardi¹, A Inno², J Foglietta³, B Cardinali⁴, L Del Mastro⁴, L Crinò³

Affiliations

¹ Department of Medical Oncology, Sacro Cuore-Don Calabria Hospital, Negrar-Verona.
² Department of Medical Oncology, Sacro Cuore-Don Calabria Hospital, Negrar-Verona. Electronic address: alessandro.inno@sacrocuore.it.
³ Department of Medical Oncology, Azienda Ospedaliera di Perugia, Perugia.
⁴ Development of Innovative Therapies Unit, Department of Medical Oncology, IRCCS-AOU San Martino-IST National Institute for Cancer Research, Genova, Italy.

PMID: 24667724
DOI: 10.1093/annonc/mdu041

No abstract available

Publication types

Letter

MeSH terms

Brain Neoplasms / cerebrospinal fluid*
Brain Neoplasms / pathology
Brain Neoplasms / secondary
Breast Neoplasms / cerebrospinal fluid*
Breast Neoplasms / pathology
Clinical Trials, Phase III as Topic
Female
Humans
Lapatinib
Quinazolines / administration & dosage
Quinazolines / cerebrospinal fluid*
Receptor, ErbB-2 / genetics

Substances

Quinazolines
Lapatinib
ERBB2 protein, human
Receptor, ErbB-2